William Leslie, NP
Family · Hillsdale, MINPI 1730756461
Payments from drug & device makers
Across 235 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$900
- AstraZeneca$512
- AbbVie$494
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$489
- Lilly USA, LLC$284
- Bayer$178
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,108100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 62 | $900 |
| AstraZeneca | 26 | $512 |
| AbbVie | 34 | $494 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $489 |
| Lilly USA, LLC | 15 | $284 |
| Bayer | 10 | $178 |
| Lundbeck LLC | 7 | $150 |
| Axsome Therapeutics, Inc. | 5 | $117 |
| Amgen | 6 | $116 |
| Inogen, Inc. | 6 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| GSK | 2 | $94 |
| Vanda Pharmaceuticals Inc. | 3 | $81 |
| Novartis | 4 | $74 |
| Viatris Specialty LLC | 2 | $65 |
| Johnson & Johnson | 3 | $51 |
| Exact Sciences | 2 | $38 |
| Pfizer | 2 | $37 |
| Corcept Therapeutics | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Boston Scientific | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Electromed, Inc. | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
How this compares
$4,108 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 128 | $103,844 |
| JardianceEmpagliflozin | 82 | $91,099 |
| FarxigaDapagliflozin Propanediol | 74 | $79,388 |
| OzempicSemaglutide | 60 | $78,531 |
| MounjaroTirzepatide | 42 | $51,410 |
| VraylarCariprazine Hcl | 29 | $42,441 |
| EliquisApixaban | 51 | $40,560 |
| JanuviaSitagliptin Phosphate | 40 | $35,502 |
| KerendiaFinerenone | 16 | $27,691 |
| XareltoRivaroxaban | 29 | $26,813 |
| RybelsusSemaglutide | 15 | $26,239 |
| EntrestoSacubitril/Valsartan | 37 | $23,194 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $18,609 |
| TrulicityDulaglutide | 16 | $16,642 |
| Spiriva RespimatTiotropium Bromide | 17 | $11,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $512 | $105,342125 claims |
| Novo NordiskOzempic, Rybelsus | $900 | $104,77075 claims |
| GSKTrelegy Ellipta | $94 | $103,844128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $284 | $68,05258 claims |
| AbbVieVraylar | $494 | $42,44129 claims |
| PfizerEliquis | $37 | $40,56051 claims |
| BayerKerendia | $178 | $27,69116 claims |
| Johnson & JohnsonXarelto | $51 | $26,81329 claims |
| NovartisEntresto | $74 | $23,19437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.
Other family in Hillsdale
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.